Neuphoria Therapeutics Ring the Nasdaq Opening Bell
news
Theodore (Ted) Ghorra
·
Andrew Reilly
·
Elaine Wangsawidjaja
·
Olivia Y. Wang
·
March 6, 2025
We congratulate our client, Neuphoria Therapeutics Inc. on their successful redomiciliation to the U.S. In celebratory fashion, Neuphoria Therapeutics Inc. rang the Nasdaq Opening Bell on March 3rd, 2025! Ted Ghorra, Andrew Reilly, Elaine Wangsawidjaja and Olivia Wang have worked regularly with this client. Read more here Rimon’s Securities and Capital Markets attorneys have decades…
Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership
news
Debbie A. Klis
·
Mark C. Lee
·
Olivia Y. Wang
·
March 5, 2025
Cyclacel Pharmaceuticals, Inc. (“Cyclacel”) (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company that develops innovative cancer medicines, announced a change in control and leadership on February 26, 2025. Datuk Dr. Doris Wong Sing Ee acquired the majority interest in Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) and will now serve as its Chief Executive Officer and Executive Director. In…
Arogo Capital Acquisition Corp announces business combination agreement with Bangkok Tellink Co., Ltd. valued at $350 million
news
Debbie A. Klis
·
Ivan Komaritsky
·
Benjamin Aguilera
·
Roy W. Gillig
·
Olivia Y. Wang
·
February 20, 2025
Rimon SPAC client Arogo Capital Acquisition Corp., announced that it has executed a business combination agreement with Bangkok Tellink Co., Ltd. Bangkok Tellink Co., Ltd. is an emerging leader in advanced telecommunications, mobile network technology, and Internet of Things (IoT) solutions. The transaction is estimated to be valued at USD$350 million and is expected to result…
Future Vision II Acquisition Corp. Announces the Closing of its $57,500,000 Initial Public Offering including Full Exercise of Underwriter’s Over-Allotment Option to Purchase Additional Units
news
Debbie A. Klis
·
Olivia Y. Wang
·
September 13, 2024
Rimon P.C. client, Future Vision II Acquisition Corp. (NASDAQ: FVNNU), today announced the closing of its initial public offering of 5,750,000 units, which includes 750,000 units issued pursuant to the underwriter’s exercise of its over-allotment option in full, which offering was priced at $10.00 per unit, resulting in gross proceeds of $57,500,000. Future Vision’s units are…
Agriculture & Natural Solutions Acquisition Corporation Announces US$510 Million Business Combination
news
Debbie A. Klis
·
Andrew Reilly
·
Benjamin Aguilera
·
Roy W. Gillig
·
Ivan Komaritsky
·
Olivia Y. Wang
·
September 3, 2024
We are pleased to announce the proposed business combination agreement between Rimon client, Australian Food & Agriculture Company Limited (AF&A), and Agriculture & Natural Solutions Acquisition Corporation, a special purpose acquisition company. Upon closing, the combined company, Agriculture & Natural Solutions Company Limited (“NewCo”), expects to be listed on the New York Stock Exchange (NYSE)…
Rimon Law adds China focused Securities and Capital Markets Attorney to Team
news
Olivia Y. Wang
·
August 29, 2024
Rimon is pleased to welcome securities and capital markets Counsel, Olivia Y. Wang, to the firm. Olivia has significant experience advising clients on a wide range of corporate and securities matters, including initial public offerings and other registered securities offerings, de-SPACs, private placements, mergers and acquisitions, public company reporting, and corporate governance matters. Olivia has a particular…
